Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Celcuity LLC (CELC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: CELC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $28.71
1 Year Target Price $28.71
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -6.09% | Avg. Invested days 39 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 524.83M USD | Price to earnings Ratio - | 1Y Target Price 28.71 |
Price to earnings Ratio - | 1Y Target Price 28.71 | ||
Volume (30-day avg) 7 | Beta 0.39 | 52 Weeks Range 7.58 - 19.77 | Updated Date 07/17/2025 |
52 Weeks Range 7.58 - 19.77 | Updated Date 07/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.05 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -39.04% | Return on Equity (TTM) -115.39% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 417845721 | Price to Sales(TTM) - |
Enterprise Value 417845721 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -7.8 | Shares Outstanding 37866400 | Shares Floating 20785601 |
Shares Outstanding 37866400 | Shares Floating 20785601 | ||
Percent Insiders 13.21 | Percent Institutions 82.08 |
Upturn AI SWOT
Celcuity LLC
Company Overview
History and Background
Celcuity LLC is a precision oncology company pursuing uniquely positioned targeted therapies to drive new hope for patients with cancer. It was founded with the goal of identifying cancer patients likely to benefit from specific therapies.
Core Business Areas
- Drug Development: Focuses on developing targeted therapies for specific cancer subtypes based on their CELsignia diagnostic platform.
- Diagnostic Services: Offers the CELsignia diagnostic platform to pharmaceutical companies and researchers to identify patient populations most likely to respond to targeted therapies in clinical trials.
Leadership and Structure
Brian Sullivan serves as the Chief Executive Officer. The company has a board of directors and a management team responsible for strategic direction and operations.
Top Products and Market Share
Key Offerings
- Gedatolisib: Gedatolisib is an investigational PI3K/mTOR inhibitor currently in clinical development for HR+/HER2- advanced or metastatic breast cancer. No market share data is currently available as it's still in clinical trials. Competitors include other PI3K inhibitors such as those from Novartis and Bayer, as well as standard-of-care hormonal therapies.
- CELsignia Diagnostic Platform: A diagnostic platform used to identify which cancer patients are most likely to respond to specific targeted therapies. Revenue derived from pharmaceutical partnerships utilizing the platform. Competitors include other diagnostic companies offering similar profiling services, such as Foundation Medicine (FMI).
Market Dynamics
Industry Overview
The precision oncology industry is rapidly growing, driven by advancements in genomic sequencing and targeted therapies. The market is competitive, with numerous companies developing diagnostic tools and targeted treatments.
Positioning
Celcuity is positioned as a precision oncology company focused on identifying patient populations most likely to respond to targeted therapies, differentiating itself through its CELsignia diagnostic platform and targeted drug development program.
Total Addressable Market (TAM)
The TAM for precision oncology is estimated to be in the billions of dollars, continually expanding with new discoveries. Celcuity is positioning itself to capture a portion of this TAM by partnering with pharmaceutical companies to apply its diagnostics and developing its own targeted therapies.
Upturn SWOT Analysis
Strengths
- Proprietary CELsignia diagnostic platform
- Targeted therapy development approach
- Partnerships with pharmaceutical companies
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on successful clinical trial outcomes
- Early stage commercialization
Opportunities
- Expanding applications of the CELsignia platform to other cancer types
- Partnering with additional pharmaceutical companies
- Advancing Gedatolisib through clinical trials and potential regulatory approval
- Acquisition by a larger pharmaceutical firm
Threats
- Competition from other diagnostic and pharmaceutical companies
- Failure of clinical trials
- Regulatory hurdles
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- FMI
- DGX
- QDEL
Competitive Landscape
Celcuity's competitive advantage lies in its CELsignia diagnostic platform's ability to identify specific patient populations, but it faces competition from larger, more established diagnostic and pharmaceutical companies. The stock symbol 'CELC' financials dictate the revenue.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on successful clinical trials and adoption of its diagnostic platform. Financial data to reflect these is reflected under the stock symbol CELC.
Future Projections: Future growth is dependent on the success of Gedatolisib's clinical trials and commercialization, as well as continued adoption of the CELsignia diagnostic platform.
Recent Initiatives: Focus on advancing Gedatolisib through clinical trials and expanding partnerships for its CELsignia platform.
Summary
Celcuity is a precision oncology company with a promising diagnostic platform and targeted therapy in development. While it faces competition and relies on clinical trial success, its unique approach to identifying patient populations for targeted therapies offers significant potential. The company needs to secure more partnerships and funding to continue its growth. Securing funding to perform tests will enable them to gather the needed diagnostic data to improve targeted therapies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Celcuity LLC company website
- SEC filings (CELC)
- Industry reports
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice. Investment decisions should be based on individual due diligence and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Celcuity LLC
Exchange NASDAQ | Headquaters Minneapolis, MN, United States | ||
IPO Launch date 2017-09-20 | Co-Founder, Chairman & CEO Mr. Brian F. Sullivan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 87 | Website https://www.celcuity.com |
Full time employees 87 | Website https://www.celcuity.com | ||
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing of CELsignia diagnostic platform. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.